Home  /  Resource Library  /  Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL

Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL

Results of a study investigating polatuzumab vedotin in combination with zanubrutinib and rituximab for elderly patients with DLBCL